Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for Treating Patients with Hyperlipidemia by Administering a PCSK9 Inhibitor in Combination with an ANGPTL3 Inhibitor

a technology of angptl3 inhibitor and hyperlipidemia, which is applied in the direction of drug composition, antibody medical ingredients, metabolic disorders, etc., can solve the problems of many high-risk patients not reaching the ldl-c level as the guideline target, and achieve the effect of reducing the serum lipoprotein level and reducing the risk of atherosclerosis

Inactive Publication Date: 2017-09-07
REGENERON PHARM INC
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention offers treatment methods for people who have high cholesterol levels and are currently not responding or tolerating standard treatments. These methods lower the levels of lipoproteins in the blood, reducing the risk of heart disease and atherosclerosis.

Problems solved by technology

However, despite the availability of such lipid-lowering therapies, many high-risk patients fail to reach their guideline target LDL-C level (Gitt et al., 2010, Clin Res Cardiol 99(11):723-733).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for Treating Patients with Hyperlipidemia by Administering a PCSK9 Inhibitor in Combination with an ANGPTL3 Inhibitor
  • Methods for Treating Patients with Hyperlipidemia by Administering a PCSK9 Inhibitor in Combination with an ANGPTL3 Inhibitor
  • Methods for Treating Patients with Hyperlipidemia by Administering a PCSK9 Inhibitor in Combination with an ANGPTL3 Inhibitor

Examples

Experimental program
Comparison scheme
Effect test

example 1

Generation of Human Antibodies to Human PCSK9

[0130]Human anti-PCSK9 antibodies were generated as described in U.S. Pat. No. 8,062,640. The exemplary PCSK9 inhibitor used in the following Example is the human anti-PCSK9 antibody designated “H1H316P,” also known as “alirocumab”, or “PRAULENT®”. H1 H316P has the following amino acid sequence characteristics: a heavy chain comprising SEQ ID NO:16 and a light chain comprising SEQ ID NO:20; a heavy chain variable region (HCVR) comprising SEQ ID NO:12 and a light chain variable domain (LCVR) comprising SEQ ID NO:17; a heavy chain complementarity determining region 1 (HCDR1) comprising SEQ ID NO:13, a HCDR2 comprising SEQ ID NO:14, a HCDR3 comprising SEQ ID NO:15, a light chain complementarity determining region 1 (LCDR1) comprising SEQ ID NO:18, a LCDR2 comprising SEQ ID NO:19 and a LCDR3 comprising SEQ ID NO:21.

example 2

Generation of Human Antibodies to Human ANGPTL3

[0131]Human anti-ANGPTL3 antibodies were generated as described in U.S. Pat. No. 9,018,356. The exemplary ANGPTL3 inhibitor used in the following Example is the human anti-ANGPTL3 antibody designated “H4H1276S,” also known as “evinacumab.” H4H1276S has the following amino acid sequence characteristics: a heavy chain comprising SEQ ID NO:10 and a light chain comprising SEQ ID NO:11; a heavy chain variable region (HCVR) comprising SEQ ID NO:2 and a light chain variable domain (LCVR) comprising SEQ ID NO:3; a heavy chain complementarity determining region 1 (HCDR1) comprising SEQ ID NO:4, a HCDR2 comprising SEQ ID NO:5, a HCDR3 comprising SEQ ID NO:6, a light chain complementarity determining region 1 (LCDR1) comprising SEQ ID NO:7, a LCDR2 comprising SEQ ID NO:8 and a LCDR3 comprising SEQ ID NO:9.

example 3

In Vivo Effect of Treatment with a Combination of an Anti-hANGPTL3 Antibody and an Anti-PCSK9 Antibody on Circulating Lipid Levels in Hyperlipidemic Ldlr− / + mice

[0132]The effect of anti-hANGPTL3 antibody H4H1276 (evinacumab) alone, anti-PCSK9 antibody H1H316P (alirocumab) alone and both antibodies in combination on serum lipids levels was determined in LDLR - / ±mice. These mice are hyperlipidemic with majority of their circulating cholesterol found in the form of LDL due to partial deficiency in LDLR, the major receptor for LDL-C uptake.

[0133]In the first study, male LDLR− / + mice on chow diet were pre-bled 5 days before the experiment and mice were put into groups of five mice each. The antibodies, H4H1276P, H1H316P, their combination and isotype-matched (hlgG4) control with irrelevant specificity, were administered at a dose of 10mg / kg each by subcutaneous injection on Day 0 of the study. Mice were bled after 4 hours of fasting on consecutive days after the antibodies injections and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
frequencyaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to proprotein convertase subtilisin / kexin type 9 (PCSK9) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-PCSK9 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit under 35 U.S.C. §119(e) of US provisional application No. 62 / 302,907, filed on Mar. 3, 2016. The disclosure of the aforementioned patent application is herein incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention relates to the field of therapeutic treatments of diseases and disorders, which are associated with elevated levels of lipids and lipoproteins. More specifically, the invention relates to the use of a proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitor in combination with an inhibitor of angiopoietin-like protein 3 (ANGPTL3) to treat patients with hypercholesterolemia and related conditions, who are non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy.BACKGROUND[0003]Hyperlipidemia is a general term that encompasses diseases and disorders characterized by or associated with elevated le...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/40A61K9/00C07K16/22
CPCC07K16/40C07K16/22A61K9/0019A61K2039/545C07K2317/56C07K2317/21A61K2039/507C07K2317/565A61K2039/505C07K2317/76A61P3/06A61P43/00A61P9/10A61K2300/00
Inventor GUSAROVA, VIKTORIAGROMADA, JESPERMURPHY, ANDREW J.
Owner REGENERON PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com